Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EBT (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed EBT for 11 consecutive years, with -$92.2 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 26.69% to -$92.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$411.8 million, a 15.35% increase, with the full-year FY2025 number at -$411.8 million, up 15.35% from a year prior.
  • EBT was -$92.2 million for Q4 2025 at Intellia Therapeutics, up from -$104.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$46.2 million in Q1 2021 to a low of -$143.7 million in Q1 2022.
  • A 5-year average of -$104.0 million and a median of -$104.2 million in 2022 define the central range for EBT.
  • Peak YoY movement for EBT: tumbled 211.02% in 2022, then surged 30.43% in 2023.
  • Intellia Therapeutics' EBT stood at -$79.9 million in 2021, then tumbled by 31.06% to -$104.7 million in 2022, then dropped by 21.67% to -$127.4 million in 2023, then grew by 1.27% to -$125.8 million in 2024, then increased by 26.69% to -$92.2 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's EBT are -$92.2 million (Q4 2025), -$104.8 million (Q3 2025), and -$102.6 million (Q2 2025).